Waters Corporation $WAT Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. reduced its position in Waters Corporation (NYSE:WAT) by 6.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 29,235 shares of the medical instruments supplier’s stock after selling 1,862 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Waters were worth $10,926,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in WAT. Brighton Jones LLC increased its stake in Waters by 112.9% during the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after acquiring an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 30 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Waters by 3.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after purchasing an additional 6,976 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Waters by 16.6% during the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock worth $415,000 after purchasing an additional 160 shares during the period. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Waters during the 2nd quarter worth about $232,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Insider Activity at Waters

In other news, Director Christopher A. Kuebler sold 3,626 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the transaction, the director directly owned 17,808 shares in the company, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.31% of the company’s stock.

Waters Stock Performance

Shares of NYSE:WAT opened at $414.90 on Friday. The company has a market cap of $40.76 billion, a P/E ratio of 103.47, a PEG ratio of 2.42 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.50 and a current ratio of 0.77. Waters Corporation has a one year low of $282.77 and a one year high of $420.26. The business’s 50-day simple moving average is $376.26 and its 200 day simple moving average is $345.85.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping analysts’ consensus estimates of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.62 billion. During the same quarter in the prior year, the business earned $2.95 EPS. Waters’s quarterly revenue was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, sell-side analysts forecast that Waters Corporation will post 14.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Bank of America raised their price target on shares of Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, June 2nd. The Goldman Sachs Group boosted their price objective on shares of Waters from $380.00 to $425.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Morgan Stanley set a $430.00 price objective on shares of Waters in a research note on Wednesday, August 5th. Wolfe Research assumed coverage on shares of Waters in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 target price on the stock. Finally, Sanford C. Bernstein began coverage on shares of Waters in a report on Friday, June 26th. They set an “outperform” rating and a $435.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $420.35.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.